SJ1008030 (formic)

• Description :

  SJ1008030 (compound 8) formic is a JAK2 PROTAC which selectively degrades JAK2. SJ1008030 formic inhibits MHH–CALL-4 cell growth with an IC50 of 5.4 nM. SJ1008030 formic can be used for the research of leukemia[1].

• UNSPSC :

  12352005

• Target :

  JAK; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; JAK/STAT Signaling; PROTAC; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/sj1008030-formic.html

• Purity :

  97.66

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  O=S(CC)(N1CC(N2C=C(C=N2)C3=C4C=CNC4=NC(NC5=CC=C(C=C5)C(NCCN6CCN(CC6)C7=CC=C8C(N(C9CCC(NC9=O)=O)C(C8=C7)=O)=O)=O)=N3)(CC#N)C1)=O.OC=O

• Molecular Formula :

  C43H45N13O9S

• Molecular Weight :

  919.96

• References & Citations :

  [1]Chang Y, et al. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood. 2021 Dec 9;138 (23) :2313-2326.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  JAK2